Cell therapy (Stem-cell derived) · Cell replacement · developed by Aspen Neuroscience
ANPD001 is a cell therapy made from the patient's own skin cells reprogrammed into induced pluripotent stem cells, then differentiated into precursors of dopamine-producing brain cells. It is being studied in Parkinson disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06344026 | Phase 1 | Parkinson Disease | Enrolling by invitation | ASPE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Parkinson Disease
Updated Nov 8, 2026. Something wrong or missing? Report it on the ASPE page.
See ASPE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ASPE catalysts and pipeline →